Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets remain buoyant
Thu, 26 Dec 01:30 pm

Indian share markets continued to trade above the dotted line in the post-noon trading session. Barring auto, all the sectoral indices are trading in the green with power, consumer durables and meta stocksl being the biggest gainers.

BSE-Sensex is up 35 points and NSE-Nifty is trading 14 points up. BSE Mid Cap is trading up 0.8% and BSE Small Cap index is trading up 1.5%. The rupee is trading at 61.9 to the US dollar.

Majority of the public sector banking stocks are trading in the green with Indian Bank and Dena bank being among the major gainers whereas Punjab & Sind Bank and Bank of Maharashtra are the only stocks trading in the red. As per a leading financial daily, banks opened record number of 7,300 branches in 2013 which is the highest in a decade. Despite the growing popularity of alternative bank channels, the brick-and-mortar branches have failed to lose attraction. Reportedly, the government’s financial inclusion programme to provide banking services across 6.25 lakh villages has led to banks setting up branches in rural and semi-urban regions. The expansion program was aided by relaxing in branch licensing norms by the Reserve Bank of India. Among state-run banks, Canara Bank opened the highest number of branches at 723 whereas largest bank State Bank of India opened 627 branches in 2013. Among private banks, ICICI Bank opened the highest number of branches at 587 during the year.

pharma stocks are trading mixed with Indoco Remedies and Orchid Chemicals being the major gainers whereas Biocon and Dishman Pharma are among major losers. As per a leading financial daily, large pharma companies such as Sun Pharma, Abbot Healthcare and Glenmark Pharmaceuticlas have still not restored the trade margins offered to drug distributors. In May 2013, the National Pharmaceutical Pricing Authority had enforced a ceiling on the prices of 348 essential medicines. As a result pharma companies cut margins on wholesalers by 2% and that of retailers by 4%. While mid-sized pharma companies restored margins after several months of negotiations that had also resulted in a disruption in the supply of drugs for a brief period but big pharma companies are still negotiating. However, companies such as Torrent Pharma, Pfizer and Ranbaxy Laboratories are offering discounts on a slightly higher stockiest selling price.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.